Avalyn Pharma (NASDAQ:AVLN) Shares Up 9.3% – Should You Buy?

Avalyn Pharma Inc. (NASDAQ:AVLN) shot up 9.3% during mid-day trading on Wednesday . The stock traded as high as $31.14 and last traded at $30.68. 206,809 shares traded hands during trading, a decline of 35% from the average session volume of 316,451 shares. The stock had previously closed at $28.07.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AVLN. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 price objective for the company. Evercore began coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective for the company. Morgan Stanley assumed coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They set an “overweight” rating and a $53.00 price objective for the company. Finally, Guggenheim assumed coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $80.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $59.00.

Avalyn Pharma Stock Up 8.7%

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Buying and Selling

In related news, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was purchased at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the transaction, the insider owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jill Carroll bought 277,778 shares of Avalyn Pharma stock in a transaction on Friday, May 1st. The shares were acquired at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.